The Building Blocks of a Successful Launch Sequence: A Strategic Regulatory Affairs Perspective

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

Developing, refining and coordinating a complex pharmaceutical launch sequence can be a significant challenge for even large global groups.  There are a myriad of market considerations on top of commercial priorities that come into play when setting the launch sequence. Bringing a strategic regulatory affairs function into these discussions is also key in order to keep the license cascade in line with the proposed launch sequence. Continue reading


Working with Pharmaceutical Big Data: What Makes a Good Analyst?

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

We are firmly rooted in the information age, and we all have plenty of it. With the abundance of pharmaceutical Big Data, real-time and real-world data, life sciences companies are ready to put all of these insights to good use. In many companies, Big Data teams are already in place to work with these insights and inform retrospective trials and other initiatives. However, filling these teams with the skilled Big Data analysts can be difficult for organizations. Pharmaceutical Big Data analysts much possess not only a strong analytical background, but also have the industry knowledge to work with insights in a meaningful way. Continue reading


Upholding Physician Fair-Market Value: It All Starts with a Formal Rate Card

Sarah Ray, regulatory affairs and safety researcher
By Sarah Ray,
Senior Research Analyst

Developing competitive rates, to recruit key industry experts has never been the easiest of tasks for life sciences companies.  Add in the additional complexity associated with Sunshine Act reporting requirements and the recruitment process become even more difficult.  In this heightened regulatory environment, recruiting top-tier physicians and other thought leader types means that companies must balance their desire to remain competitive with adhering to rates that do not fall too far astray of physician fair-market values. Continue reading


MSLs, KPIs and Value: A Numbers Game That Teams Have to Play

Natalie DeMasi, clinical development and medical affairs researcher
By Natalie DeMasi,
Research Analyst

Medical science liaisons (MSLs) are invaluable to the life science industry.  Through interactions with thought leaders, MSLs build relationships with physicians, gain competitive intelligence, learn prescribing behaviors and bolster the company’s public image.  Unfortunately, not all of upper management understands the value that MSLs bring to the internal organization.  In fact, 63% of surveyed MSL teams struggle to prove value to upper management, according to a new report by Cutting Edge Information. Continue reading


Pharmaceutical Call Centers: Agents on the Frontlines of Physician Communication

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

When frontline communication with doctors comes to mind, many life sciences companies will turn to the commercial side of their organization.  After all, pharma sales reps are the ones touching base with physicians and presenting the product to them. But within their medical information groups companies should also look to pharmaceutical call centers for another perspective on how doctors are approaching and using their products. Continue reading


Supplementing Patient-Reported Outcomes: How Accurate Are Patient-Reported Data Online?

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

The pharmaceutical industry’s interest in patient-reported outcomes (PROs) has steady grown since the FDA and EMA released their respective guidances on the subject.  Now, pharma and device companies seek out the best ways to infuse their product support with the patient voice.  For many companies, this can mean looking not only to clinical trials which use PRO measures, but also to available pharmaceutical Big Data. As the patient population becomes more tech savvy, more and more patient data is available online. Continue reading


Medical Device HEOR Groups Use PROs to Support Reimbursement Conversations

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

Health economics groups are facing more competitive reimbursement processes worldwide.  To navigate these increasingly difficult negotiations, many medical device HEOR groups are looking to patient-reported outcomes (PROs) to improve their value propositions. One interviewed HEOR consultant explained, “Before PROs, you had a lot of clinician-completed measures and clinician rating scales. Now the FDA and stakeholders want to see how treatments are actually impacting patients, and PROs give the patients a voice in the trial.” Continue reading


The Superstars of Digital Healthcare: MM&M Lists ‘Top 40 Healthcare Transformers’

Sarah Ray, regulatory affairs and safety researcher
By Sarah Ray,
Senior Research Analyst

Innovations abound within the pharmaceutical digital marketing space. As a whole, the industry has worked to increase the availability of healthcare information and better address the needs of healthcare consumers. In its recent “Top 40 Healthcare Transformers” article, Medical Marketing and Media provides a snapshot of some of the leading industry innovators.  Many executives have leveraged online platforms to connect with unique industry stakeholders.  Others have modified the way patients receive healthcare by creating new—or rethinking existing— telemedicine platforms.  In some cases, companies have even begun connecting patients with doctors who are prepared to make house calls.  Continue reading


Pilot New Medical Science Liaison Programs with Contract MSLs

David Richardson, pharmaceutical commercialization and launch expert
By David Richardson,
Director of Research

Life sciences companies point to the outsourcing of MSLs as a way for field-based medical teams to pilot new programs and activities while avoiding the risks of taking on fulltime headcount.  Whether the activity is HEOR, managed care, or whether it is testing a hybrid medical science liaison position, it is fairly simple to contract one or two experienced MSLs to pilot it out in the field, see how it goes, and then learn the results. Continue reading